Related by context. All words. (Click for frequent words.) 66 prokinetic agent 63 gastrointestinal disorders ATI 63 Revimmune TM 62 Entereg R 61 MediGene focuses 61 thalidomide Thalomid 60 hypoxia activated prodrug 60 Zemiva TM 60 Evoltra ® 60 acetonide FA 59 Sudhir Agrawal D.Phil 59 Selzentry Celsentri 59 Xcytrin R 59 erlotinib Tarceva ® 59 MAGE A3 ASCI 59 #I TM# 59 kidney urologic 59 herpetic keratitis 59 ocular formulation 58 fusion enhancers 58 ALK inhibitors 58 neovascular diseases 58 catheter occlusion 58 rheumatoid arthritis osteoarthritis ankylosing 58 oral transdermal 58 acyclovir Lauriad R 58 Soliris TM eculizumab 57 sodium stibogluconate 57 MAbs targeting 57 novel oral anticoagulant 57 MCSP respectively 57 OvaRex R 57 PDE# inhibitors 57 INVANZ 57 ospemifene 57 Kepivance 57 Acute Radiation Syndrome 57 tubulin inhibitor 57 BCR ABL inhibitors 57 docetaxel Taxotere ® 57 receptor tyrosine kinase inhibitor 57 vaginal lidocaine 57 Pagoclone 57 Orally administered 57 immunotherapeutic approaches 57 oral prodrug 56 cMET 56 rALLy 56 hereditary deficiency 56 YONDELIS R 56 GEM OS2 56 Perforomist ™ Inhalation Solution 56 HCV protease inhibitors 56 Akt inhibitor 56 clevidipine 56 Xerese 56 humanised monoclonal antibody 56 multitargeted 56 Anidulafungin 56 Darinaparsin 56 galiximab 56 AVI antisense 56 diagnostic molecular imaging 56 MEK inhibitors 56 6R BH4 56 injectable depot 56 complement Coblation within 56 AzaSite Plus 56 MGN# 55 Optiquel ™ 55 targeting refractory relapsing 55 UPLYSO 55 topical anti infectives 55 Aquoral TM 55 macrolide antibiotic 55 CINQUIL 55 PANVAC VF 55 EndoTAG TM 55 Preclinical studies suggest 55 pain palliation 55 Pazopanib 55 coagulation disorders 55 topical antifungal 55 adipiplon 55 cytotoxics 55 antineoplastic 55 Telintra 55 demonstrated antitumor activity 55 marketed pegylated interferons 55 lucinactant 55 Silodosin 55 CINTREDEKIN BESUDOTOX 55 immuno modulatory 55 p# inhibitor 55 porcine derived 55 gastrointestinal mucositis 55 Orphan Drug designations 55 Zybrestat 55 rheumatoid arthritis psoriatic arthritis 55 Apoptone 55 NB S# strontium malonate 55 anti angiogenic agents 55 ularitide 55 oncologic diseases 55 RH1 55 Onalta ™ 55 proteasome inhibitor 54 PEG SN# 54 GALNS 54 Cancidas 54 severe hypersensitivity reactions 54 Linjeta TM 54 FACTIVE tablets 54 lumiliximab 54 Pimavanserin 54 Bioheart MyoCell 54 Excellagen 54 Voraxaze ™ 54 indiplon capsules 54 myeloproliferative diseases 54 Carfilzomib 54 regenerating bone 54 Phenoptin 54 haematologic 54 relapsed leukemia 54 factor TNF 54 GED aPC 54 TLR antagonists 54 ENTEREG ® 54 nucleoside analogs 54 macrolide antibiotics 54 CYT# vascular disrupting 54 Sanvar R 54 Intravitreal injections 54 zileuton 54 respiratory allergy dermatological 54 BEMA TM LA 54 Archexin 54 radiotherapeutic 54 Troxatyl 54 GLP toxicology studies 54 calcineurin inhibitors 54 esophageal candidiasis 54 Levulan ® PDT 54 bosutinib 54 benign prostatic hypertrophy BPH 54 Gleevec Glivec 54 ARIKACE ™ 54 recurrent herpes labialis 54 Fast Track designations 54 include GALNS N 54 oropharyngeal candidiasis 54 Behcet uveitis 54 ELIQUIS 54 LHRH analogues 54 lorvotuzumab mertansine 54 lung pancreatic 54 topical antimicrobial 54 LEP ETU 54 dermatologic diseases 54 Budesonide foam crofelemer 54 ophthalmology dermatology 54 rheumatoid arthritis juvenile idiopathic 53 Dementia Related Psychosis 53 SAR# [004] 53 MYLOTARG 53 drug ISA# 53 nosocomial pneumonia 53 Squalamine 53 BrachySil TM 53 P#X# antagonist 53 Applied Therapeutics ENT 53 treatmentof 53 INVEGA ® 53 Poly ICLC 53 injectable formulations 53 systemic immunosuppressive drugs 53 Cx# [002] 53 papillary renal cell carcinoma 53 Kamada AAT 53 Tyzeka Sebivo 53 canagliflozin 53 CA9 SCAN 53 LEUKINE 53 lymphomas leukemias 53 Sorafenib Nexavar 53 antiangiogenic therapy 53 AMPK activators 53 mTOR inhibitors 53 thetreatment 53 superficial basal cell carcinoma 53 immunological disorders 53 evaluating Prochymal 53 oral antiviral 53 taxane resistant 53 Afatinib 53 huC# DM4 53 venous stasis ulcers 53 polycythemia vera PV 53 Hemospan 53 TransVax ™ 53 Q#IR 53 AQUAVAN R 53 investigational therapies 53 cefixime 53 Gastrointestinal Stromal Tumors 53 lapatinib Tykerb 53 IMiDs ® compound 53 vidofludimus 53 PresbyLens ® 53 antiangiogenic agents 53 solanezumab 53 SYN# 53 Augment Injectable 53 HQK 53 candidates Dyloject TM 53 MYCAMINE 53 Tredaptive 53 isavuconazole 53 Phase IIb clinical trials 53 TRAIL receptor antibodies 53 oral antifungal 53 pancreatic prostate 53 imexon 53 Zemplar 53 cannabinor 53 blood clot dissolving 53 oral picoplatin 53 eTag assays 52 rThrombin 52 omeprazole sodium bicarbonate 52 Levulan PDT 52 AGGRASTAT ® tirofiban hydrochloride 52 nalbuphine ER 52 tramiprosate Alzhemed TM 52 Synavive 52 lenalidomide Revlimid R 52 lintuzumab SGN 52 Ceflatonin 52 TBC# 52 Pemetrexed 52 YONDELIS 52 volociximab 52 Shigamabs ® 52 immune modulating 52 AQ4N 52 GTC recombinant human 52 metastatic GIST 52 Zoraxel 52 OvaRex ® MAb 52 omeprazole widely 52 Aplidin 52 CytoSorb TM 52 JAK2 inhibitors 52 acute HAE attacks 52 Targretin 52 Troxatyl TM 52 treat enlarged prostate 52 www.soliris.net 52 MOZOBIL 52 alvespimycin 52 Sebivo 52 PROVIGIL 52 interventional therapies 52 recombinant interferon 52 Gleevec imatinib mesylate 52 preclinical efficacy 52 PulmoBind TM 52 VEGF inhibitors 52 renal anemia 52 Aviptadil 52 TREANDA 52 short acting bronchodilator 52 Adentri 52 IL# PE 52 DAVANAT 52 Vitaxin 52 preclinically 52 RhuDex R 52 Benlysta belimumab 52 pharmacological therapies 52 Ventavis ® 52 ProLindac TM 52 oral dnaJP1 52 Phase Ib II 52 Removab 52 TASKi3 51 BACcel 51 Plenaxis R 51 Alzhemed TM 51 therapeutic regimens 51 Zemplar Capsules 51 pulmonary hypertension PH 51 Campath ® 51 immunomodulatory therapy 51 NP2 Enkephalin 51 ostarine 51 Tarceva TM 51 liquid fibrin sealant 51 hematologic cancers 51 Valdoxan 51 BrachySil 51 Exelixis compounds 51 incyclinide 51 Vascugel ® 51 Tekamlo 51 thrombolytics 51 PET tracers 51 Cotavance 51 TheraCIM 51 OMAPRO 51 Nimotuzumab 51 colorectal liver metastases 51 vitro ADME 51 relapsed MCL 51 initiate Phase 1b 51 perampanel 51 leading oral taxane 51 Xyfid 51 Cephalon Oncology 51 Cerashield 51 ruxolitinib 51 riociguat 51 vismodegib 51 IMA# 51 amrubicin 51 deforolimus 51 pyrimethamine 51 Mesafem 51 diagnostic biomarkers 51 acute decompensated heart 51 ZOLINZA 51 TMP SMX 51 efficacy tolerability 51 pharmacodynamic markers 51 Naproxen sodium 51 topical NSAIDs 51 PROCRIT ® 51 non selective NSAIDs 51 dermaPACE TM 51 SOM# 51 NuroPro R 51 Temodar ® 51 GLASSIA 51 PRT# 51 elotuzumab 51 Granisetron Hydrochloride Injection 51 skeletal metastases 51 Corlux 51 #D#C# 51 antiplatelet medications 51 cognitive impairment associated 51 Somatuline Autogel 51 hyperimmune products 51 chronic hyperuricaemia 51 Gaboxadol 51 recurrent metastatic ovarian cancer 51 urate lowering 51 cediranib 51 Restanza demonstrated 51 Alequel 51 refractory CTCL 51 Serdaxin 51 ADVEXIN therapy 51 PulmoBind 51 ZACTIMA 51 genotypic resistance 51 Fibrillex 51 bardoxolone 51 Icatibant 51 follicular Non Hodgkin 51 omega interferon 51 gastroenterology neurology 51 AZX# 50 ganaxolone 50 Amgen denosumab 50 injectable antibiotics 50 acadesine 50 capsule formulation 50 SNT MC# 50 VDAs 50 antiarrhythmic 50 regenerative stem cell 50 fibrotic diseases 50 Octreolin 50 topical NSAID 50 either acutely decompensated 50 Zavesca R 50 OHR/AVR# 50 IOP lowering 50 antiangiogenic activity 50 TLR9 mediated immune 50 somatostatin analogues 50 radezolid 50 infused intravenously 50 HuMax CD4 50 Combo Stent 50 budesonide foam 50 Stedivaze 50 liquid embolic 50 PerClot 50 initiate Phase 2b 50 post surgical adhesions 50 therapeutic modalities 50 nasal formulation 50 pharmacologic stress 50 KETEK 50 dimebon latrepirdine 50 antiplatelet therapies 50 canakinumab 50 ThermoDox R 50 heavily pretreated 50 thrombolytic agent 50 Vicinium TM 50 CONBRIZA 50 TORISEL 50 candidiasis 50 peripheral vascular stent 50 samalizumab 50 rheumatologic 50 intranasal delivery 50 pegylated interferons 50 TLR8 agonist 50 cIAI 50 tamibarotene 50 neratinib 50 class mGluR5 inhibitor 50 lipid lowering therapies 50 Candesartan 50 Trofex TM 50 ticagrelor Brilinta 50 overlapping toxicities 50 PI3K inhibitors 50 molecular imaging radiopharmaceuticals 50 vinca alkaloid 50 Diabetic Macular Edema 50 pharmacotherapeutic 50 NCCN Compendium 50 LE DT 50 Virulizin ® 50 ESBA# 50 surgical prophylaxis 50 remitting Multiple Sclerosis 50 ANCHOR trial 50 treat GI GVHD 50 tumor necrosis 50 Aerosurf 50 Neulasta ® 50 Urocidin 50 squalamine 50 CAELYX 50 allogeneic HSCT 50 superficial bladder cancer 50 colorectal lung 50 relapsing remitting MS RRMS 50 FIRMAGON 50 hypocalcaemia 50 lenalidomide dexamethasone 50 EEG abnormalities 50 antiresorptive 50 Prodarsan ® 50 FUSILEV 50 briakinumab 50 letrozole Femara 50 investigating Serdaxin 50 CytoSorb 50 eculizumab therapy 50 Martin Nicklasson CEO 50 antiarrhythmic drug 50 initiate Phase IIa 50 nosocomial pneumonia NP 50 Sandostatin LAR Depot 50 gastrointestinal stromal tumors GIST 50 deferiprone 50 KNS # 50 thromboembolic disease 50 AA Amyloidosis 50 PXD# 50 tezampanel 50 Fortical R 50 rALLy trial 50 inhaled iloprost 50 Phase Ib study 50 corneal wound 50 symptomatic paroxysmal AF 50 gemifloxacin 50 ocular infections 49 BEXXAR 49 arbaclofen 49 CELVAPAN H#N# 49 intravenous formulations 49 tyrosine kinase inhibitor TKI 49 transgenically produced product 49 multiple myeloma MM 49 cardio renal 49 NEUVENGE 49 molecular chaperone regulation 49 secondary efficacy endpoints 49 cytotoxic therapies 49 pomalidomide 49 DEEP AF 49 DepoBupivacaine TM 49 VeraTag 49 vitreoretinal disorders 49 Mipomersen 49 fostamatinib disodium 49 containing LABAs 49 Aggrastat ® tirofiban hydrochloride 49 SMT C# 49 Pseudomonas aeruginosa infections 49 OXi# 49 ASG 5ME 49 BEMA Buprenorphine 49 Vascugel R 49 Lixivaptan 49 hematologic malignancies 49 ocular allergy 49 BLA filing 49 Rhucin ® 49 oncology indications 49 Fibrillex TM 49 ASONEP 49 triglyceride lowering 49 TELCYTA 49 peripheral vasculature 49 Syndrome RLS 49 atherothrombotic events 49 rufinamide 49 PROCHYMAL 49 fidaxomicin Phase 49 AMPAKINE CX# 49 FRAGMIN R 49 Edurant 49 receiving VELCADE 49 velafermin 49 maribavir 49 CINOD 49 Torsades de Pointes 49 noninfectious uveitis 49 ADAGIO study 49 Golimumab 49 Zavesca r 49 generation proteasome inhibitor 49 Evicel 49 Raptiva ® 49 Sutent sunitinib 49 haematological cancers 49 pegfilgrastim 49 Pharmos pipeline 49 genomic biomarkers 49 Tindamax 49 HyQ 49 TOCOSOL Camptothecin 49 PLX cells 49 Phase IIB clinical 49 oral anticoagulants 49 Hedgehog antagonist 49 TriMix gel TM 49 dexanabinol 49 Cethrin 49 GP IIb IIIa inhibitors 49 talactoferrin 49 Tamibarotene 49 telomerase inhibition 49 haematological malignancies 49 SUSTENNA TM 49 embolotherapy 49 antiangiogenic drugs 49 Pre RELAX AHF 49 Phase #/#a trial 49 GRN# 49 HIFU therapy 49 RSD# oral 49 EECP R 49 hypersensitivity allergic reactions 49 circulating endothelial cells 49 molecular biomarkers 49 hematological indications 49 patients undergoing percutaneous 49 VeraTag technology 49 Sublative Rejuvenation 49 TYZEKA 49 inhibit angiogenesis 49 serologically active systemic lupus 49 Twinrix 49 PGL# 49 Pharmacodynamic 49 Ganetespib 49 Smac mimetic 49 TroVax ® 49 Eltrombopag 49 Altrazeal R 49 NeuroStar TMS Therapy 49 XL# XL# XL# XL# 49 connective tissue diseases 49 ZYBRESTAT fosbretabulin 49 BRAF inhibitors 49 Stakeholder Opinions 49 oral anticancer 49 XEN# 49 estramustine 49 anti angiogenic drugs 49 Efficacy Trial 49 hematological cancers 49 TransVax 49 hypervascular tumors 49 eliglustat tartrate 49 NATRECOR ® 49 NCCN guidelines 49 ie antibody mediated 49 metastatic sarcoma 49 CA4P 49 somatostatin receptor 49 sirtuin activators 49 Rezular 49 imatinib resistance 49 ALN HTT 49 oral RSD# 49 Recoverable PGM ounces 49 monoclonal antibody therapies 49 commercialize deforolimus 49 liposomal formulations 49 POSIDUR TM 49 sells Osteocel R 48 MDS AML 48 enzyme immunoassay EIA 48 nabilone 48 gepirone ER 48 indolent NHL 48 cardio metabolic 48 SURFAXIN r 48 paclitaxel poliglumex 48 histologies 48 rituximab refractory follicular 48 phase IIa clinical 48 fidaxomicin Phase 3 48 SIMPONI ® 48 non squamous histology 48 NEUMUNE 48 atrial tachyarrhythmias 48 antithrombotic agents 48 pelvic malignancies 48 TNF alpha inhibitors 48 receiving TNF blockers 48 reversing heparin 48 ACCLAIM II 48 Angiox 48 LymphoStat B 48 preclinical pharmacology 48 gastric pancreatic 48 intravesical therapy 48 rhC1INH 48 Toraymyxin 48 recombinant factor VIIa 48 HGS ETR2 48 PS# DARA 48 registrational 48 5 HT6 receptor 48 Phase IIb III 48 arsenic trioxide ATO 48 Visian Toric ICL 48 Shows Efficacy 48 dermatology urology gynecology orthopedics 48 oxypurinol 48 preclinical pharmacokinetic 48 Protelos 48 IGF IR 48 DEFLUX 48 procedural sedation 48 refractory acute myeloid 48 IIa trials 48 Diovan HCT 48 Visipaque 48 SIR Spheres 48 florbetaben 48 ganetespib 48 relapsed ovarian cancer 48 please visit www.advaxis.com 48 VNP#M 48 COLAL PRED 48 FVIIa 48 ophthalmology dermatology cardiovascular disease 48 demonstrated clinically meaningful 48 EGFRIs 48 Phase IIb trials 48 Tasigna prolongs 48 RoACTEMRA 48 trabectedin 48 multiple sclerosis rheumatoid arthritis 48 Tasimelteon 48 phase Ib 48 PRIMO CABG 48 uric acid lowering 48 NeoLipid drug 48 bardoxolone methyl 48 immunological diseases 48 Millennium Velcade 48 compound Protectan CBLB# 48 SIRT1 activators 48 Max Neeman International 48 peritoneal dialysis PD 48 venous leg 48 pediatric malignancies 48 pharmacological approaches 48 MKC# PP 48 radiochemotherapy 48 pharmaceuticals biologics 48 cMET inhibitor 48 ritonavir boosted protease inhibitor 48 OMS#HP 48 diabetic retinopathy DR 48 registrational trials 48 ponatinib 48 Pirfenidone 48 Tracleer r 48 IVIg 48 VIBEX MTX 48 PNH patients 48 EGFR mutation positive 48 phase IIb study 48 vascular disrupting agent 48 CytoFabTM 48 BioNumerik 48 mTOR inhibition 48 SEPET TM 48 therapeutic armamentarium 48 generation URAT1 inhibitor 48 topical formulations 48 Factor Xa inhibitors 48 novel trazodone formulation 48 DRX# ™ 48 INTEGRILIN R 48 neuro stimulation 48 LLLT 48 ICA # 48 endovascular stent grafts 48 cetuximab Erbitux 48 neuro vascular 48 CR# vcMMAE 48 nephrology oncology 48 mGluR5 NAM 48 radionuclide therapy 48 TQT studies 48 KIACTA ™ 48 anti androgens 47 tecarfarin 47 aldosterone antagonists 47 clinical trials dacetuzumab SGN 47 Actemra tocilizumab 47 MAXY alpha 47 Aurexis 47 skeletal sarcomere activator 47 endothelin antagonist 47 autoimmune uveitis 47 antidiabetes 47 spinal manipulative 47 renin inhibition 47 treating cancerous tumors 47 Angiox R 47 parasitological 47 vosaroxin 47 recurrent metastatic 47 Allovectin 7 ® 47 gastroenterology orthopedics 47 AVERROES 47 dosed orally 47 urocortin 2 47 Biodegradable Polymers 47 Ventavis 47 ranibizumab Lucentis 47 Phase IIA 47 Phase IIIb clinical 47 AngioSculpt Scoring Balloon Catheter 47 mupirocin 47 vivo toxicology 47 lupus nephritis 47 luliconazole 47 tanespimycin 47 Solesta 47 Hepatocellular Carcinoma HCC 47 Oxiplex 47 influenza antiviral medications 47 ritonavir boosted danoprevir 47 S/GSK# 47 DGAT1 inhibitors 47 neurostimulation devices 47 adipose derived stem cell 47 www.sorin.com 47 TNF blocking 47 Hypotension 47 esophagogastric 47 SPARLON 47 K ras mutations 47 forodesine hydrochloride BCX 47 favorable pharmacokinetic profile 47 elevated creatine phosphokinase 47 Ferinject ® 47 thrombolytic agents 47 enzastaurin 47 brostallicin 47 Rhucin R 47 neuropsychiatric events 47 CML CP 47 Cyanokit 47 Severe VOD 47 argatroban 47 Phase IIa clinical trials 47 clinical trials SGN 47 GATTEX ™ 47 IND submission 47 vitamin D analogs 47 Cites Positive 47 oncologic 47 Lu AA# 47 romidepsin 47 lung cancer NSCLC 47 hemostatic agents 47 hematological tumors 47 Phase IIIB IV 47 midstage studies 47 empiric therapy 47 somatostatin analogs 47 Vaxfectin R formulated 47 HAp 47 CDK inhibitors 47 noninvasive diagnostic 47 uridine triacetate 47 renal toxicity 47 DITPA 47 includes TOLAMBA TM 47 microwave hyperthermia 47 REMUNE R 47 ABLAVAR ® 47 unresectable liver cancer 47 Symadex 47 Jean Jacques Garaud 47 APTIVUS ritonavir 47 randomized controlled multicenter 47 accelerating dermal 47 Nicole Onetto MD 47 COMT inhibitors 47 paliperidone ER 47 anti EGFR antibody 47 triphendiol 47 Orathecin 47 refractory angina 47 pouchitis 47 Aclasta Reclast 47 Secca System 47 Vivaglobin 47 phase IIb trial 47 Disease Modifying 47 antidiabetic medications 47 SIMPONI TM 47 anticancer therapy 47 intra arterial chemotherapy 47 Rheumatoid Arthritis Drug 47 Spectranetics laser 47 cidofovir 47 COREG CR 46 Evoltra TM 46 Resolute DES 46 Apo2L 46 chemopreventive agent 46 motesanib 46 RRMS patients 46 immunology oncology 46 Prestara 46 DU #b 46 PI3 kinase inhibitors 46 chronic ITP patients 46 microsphere therapy 46 HIV associated lipodystrophy 46 valopicitabine 46 Cardiac Cryoablation System 46 neurology cardiology 46 unstable angina UA 46 acute PAO 46 gynecologic procedures 46 supratherapeutic doses 46 hemagglutination inhibition HAI 46 KRAS status 46 NovoTTF 46 Src inhibitors 46 Functional Somatic Syndromes 46 PROSTVAC ® 46 TYSABRI therapy 46 multicenter clinical trials 46 iii Cubist 46 adult chronic ITP 46 romiplostim 46 Nivestim 46 Nanocort 46 myeloproliferative neoplasms MPNs 46 PROSTVAC TM 46 AZILECT ® 46 forodesine HCl 46 please visit www.medlinkus.com 46 iroxanadine 46 IGRAs 46 pivotal bioequivalence 46 rivaroxaban Xarelto 46 Oncophage vitespen 46 Wound Therapy 46 Rifamycin SV MMX 46 RGB # 46 opiate analgesics 46 Phenserine 46 plasminogen activators 46 interferon beta therapy 46 IIa trial 46 oral FTY# 46 Zavesca ® 46 biodegradable implant 46 OMP designation 46 betrixaban 46 Memryte 46 Rh proteins 46 gastroenterological 46 virus HBV infection 46 renal denervation 46 biologic DMARDs 46 protein misfolding diseases 46 stent coating 46 EVICEL 46 malignant pheochromocytoma 46 PONV 46 inhaled bronchodilators 46 nonclinical studies 46 MMP inhibitors 46 rituximab Rituxan ® 46 hematologic tumors 46 PASI scores 46 DACH platinum 46 Active Ulcerative Colitis 46 Orazol 46 Reclast Aclasta 46 axitinib 46 studies evaluating satraplatin 46 rheumatic disorders 46 IGIV 46 NeutroPhase 46 DDW ® 46 MyVax personalized immunotherapy 46 e2 Collector 46 COMFORT II 46 Oxycyte 46 Altrazeal ® 46 polidocanol 46 aortic stent grafts 46 Asentar 46 ozarelix 46 PRECISE Trial 46 asymptomatic hyperuricemia 46 Hedgehog inhibitor 46 Mammosite 46 dermatologic 46 Product Characteristics 46 Candida infection 45 Tavocept 45 Altrazeal 45 IPLEX 45 antibiotic vancomycin 45 Phase IIa trial 45 Flutiform ™ 45 OZURDEX ® 45 potent neuroprotective 45 angiogenesis inhibition 45 heterozygous FH 45 oncology urology 45 R alvimopan 45 refractory Hodgkin 45 ERBITUX Cetuximab 45 XIENCE V stent 45 Rylomine TM 45 tumor malignancies 45 metastatic RCC 45 PENNVAX B 45 antiarrhythmic drugs 45 bone grafting procedures 45 Calmare Pain Therapy 45 elacytarabine 45 anticancer activity 45 orthoPACE 45 Serdolect 45 oral PTH 45 NovoTTF #A System 45 Prodarsan 45 Doribax 45 chemotherapeutic regimens 45 multiparametric 45 Orphan Drug status 45 LUMINATE 45 REMICADE ® 45 Maximum Tolerated Dose MTD 45 Kaletra tablets 45 Pharmacokinetic parameters 45 PulmoBind ™ 45 InterStim Therapy